In addition to Jason Cole, 9 other BLUE executives reported Sell trades in the last month.
Based on Bluebird Bio’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $199 million and GAAP net loss of -$21,465,000. In comparison, last year the company earned revenue of $13.3 million and had a GAAP net loss of $196 million. The company has a one-year high of $99.36 and a one-year low of $38.95. Currently, Bluebird Bio has an average volume of 492.45K.
Based on 12 analyst ratings, the analyst consensus is Strong Buy with an average price target of $99.80, reflecting a -43.5% downside.
The insider sentiment on Bluebird Bio has been negative according to 75 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.